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ABSTRACT  
 
The aim of the present study was to correlate the presence and extent of retraction clefting and 
the expression of p63 in neoplastic glands and glands with prostatic intraepithelial neoplasia 
(PIN) in needle core biopsies.  
We analyzed needle core biopsies from 28 patients with PIN and 41 patients with 
adenocarcinoma. Neoplastic glands and those with PIN were analyzed on high power field 
(400x) and classified in three groups. Immunohistochemical staining was performed 
following Microwave Streptavidin ImmunoPeroxidase (MSIP) protocol on DAKO TechMate 
Horizon automated immunostainer using antibodies to p63 (4A4, M7247, DAKO, Denmark). 
Periacinar retraction clefting was significantly more prominent in prostatic carcinoma 
compared to PIN (p<0.0001) and nonneoplastic glands (p<0.0001). There was no difference 
between normal glands and PIN regarding clefting (p=0.8064). P63 was positive around 
whole circumference in 12 out of 28 cases with PIN, and discontinuously positive in 
remaining 16 PIN cases suggesting initial disruption of basal cell layer. P63 immunostaining 
was also positive in all nonneoplastic glands, and negative in all carcinoma cases.  
We conclude that retraction clefting was associated with cancer and lack of basal cells, but 
not with PIN. The relationship between clefting and p63 immunostaining in prostatic cancer 
should be further analyzed. 
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INTRODUCTION 
 
The diagnosis of prostatic carcinoma is based on three major histologic criteria; the infiltrative 
growth pattern, the absence of a basal cell layer and the presence of macronucleoli.1,5 The 
ability of immunohistochemical staining to detect basal cells has proven to be diagnostically 
invaluable, especially in needle biopsy specimens. P63, a homologue of the tumor suppressor 
gene p53, has been shown in the basal cell component of epithelium from a variety of tissues, 
including prostatic epithelium.16,20,25 Value of p63 immunostaining in the diagnosis of 
prostatic adenocarcinoma has been clearly shown.25   
Prostatic intraepithelial neoplasia (PIN) is the most likely precursor of prostatic 
adenocarcinoma according to available data from the literature.1,14,19. PIN is the abnormal 
proliferation within the prostate ducts, ductules and large acini of premalignant foci of cellular 
dysplasia and carcinoma in situ without stromal invasion.1,14,19 There is preservation of the 
basal cell layer and basement membrane, however focal disruption of basal cell layer may be 
observed.19 The incidence of PIN varies according to type of bioptic material. PIN is 
associated with progressive abnormalities of phenotype and genotype.2,19     
One of the criteria favoring prostatic adenocarcinoma is the presence of retraction 
clefting around neoplastic glands.11,12,24 The neoplastic cells of prostatic cancer often appear 
pulled away from the surrounding stroma leaving retraction artifacts around the acini.8,9 These 
retraction artifacts, periacinar halos or so-called retraction clefting are often observed, 
especially in Gleason pattern 3 prostatic carcinomas. It was shown that periacinar retraction 
clefting represents a reliable criterion for diagnosis of prostatic adenocarcinoma in needle 
core biopsies, especially in cases with clefts affecting more than 50% of circumference in at 
least 50% of suspicious glands.11,12 A correlation of periacinar retraction clefting between 
needle core and corresponding prostatectomy specimens was found and therefore confirmed 
clefting as the criterion for diagnosis of the prostatic adenocarcinoma.12  It was suggested that 
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this phenomenon is probably connected to the lack of basal cells. To analyze further this idea 
the study was aimed to correlate the presence and extent of retraction clefting and the 
expression of p63 in neoplastic glands and glands with prostatic intraepithelial neoplasia in 
needle core biopsies. 
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MATERIAL AND METHODS 
 
Thirty-seven consecutive cases with high-grade intraepithelial neoplasia and 56 cases with 
prostatic carcinoma diagnosed during one year on the basis of major and favoring criteria at 
the Department of Pathology Sestre milosrdnice University Hospital, Zagreb, Croatia were 
chosen for the study. The patients underwent prostatic needle core biopsy after having an 
increased PSA serum value. The urologists pull needle core biopsies from different areas of 
the prostate into 6 to 12 parts, usually maintaining orientation of the side and the part of 
prostate where biopsies were taken. An improved preembedding method was applied. Before 
fixation biopsy specimens were stretched and placed in tissue cassettes between two nylon 
meshes by the urologist immediately after biopsy. The tissue cassettes were submitted in 
containers filled with 10% buffered formalin. 17,18   
On the hematoxylin and eosin slides, all chosen tumors consisted of at least 30 or more 
neoplastic glands and in nontumorous part of specimens there were at least 30 or more 
nonneoplastic glands. After immunohistochemical procedure fifteen cases were excluded 
from the study because in deeper sections did not contain sufficient number of glands for 
observation (minimally 30 neoplastic and nonneoplastic glands). The same problem with 
deeper sections was observed in 9 cases with PIN that were also excluded from the study. 
There were 28 PIN cases with one to three glands (mean 1.28) in patients ranging in age from 
53 to 84 years (mean 65.8 years) with the PSA value from 4.2 to 121 ng/ml. 
The study included forty-one patients with carcinoma who ranged in age from 53-82 
years (mean 68.1 years). PSA value ranged from 4.2 to 381 ng/ml. Specimens were fixed in 
10% buffered formaldehyde, embedded in paraffin, and cut at 5 μm thickness and routinely 
stained with hematoxylin and eosin. In some cases material was stained by HMW-CK and 
alcian-PAS. Alcian-PAS positive staining was not used as the only criterion since it is well 
known that such positivity might be seen in mimickers of cancer such as atrophy and 
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adenosis. Glands with PIN were analyzed on high power field (400x) and classified in three 
groups as follows. Group I with no clefting, group II with clefting, which affected up to 50% 
of gland circumference and group III glands with clefts, which affected more than 50% of 
gland circumference. Clefting in neoplastic and nonneoplastic specimens were analyzed on 10 
neoplastic and 10 normal glands in three different high power fields. Neoplastic and 
nonneoplastic glands were also classified in three groups; group I with no clefting or no clefts 
which affected more than 50% of circumference of glands, group II with up to 50% of glands 
(up to fifteen out of thirty) showing clefting that affected more than 50% of circumference 
and group III with retraction clefting affecting more than 50% of circumference in 50% or 
more glands (fifteen or more out of thirty). Clefting at the edges of a biopsy and cleft-like 
spaces in glands with incomplete circumference were excluded from examination, as at least 
some of it is likely to be a consequence of sectioning. Immunohistochemical staining was 
performed following Microwave Streptavidin ImmunoPeroxidase (MSIP) protocol on DAKO 
TechMate Horizon automated immunostainer using antibodies to p63 (4A4 M7247, DAKO, 
Denmark). As a control we used normal glands within the same biopsy. 
Statistical analysis was performed using χ2 test. The level of significance was set at 0.05.  
 
                    
 
8
 
RESULTS 
 
In glands with prostatic intraepithelial neoplasia clefts affecting more than 50% of gland 
circumference were not found. There were 5 PIN cases with clefting affecting less than 50% 
of circumference (Group II) and 23 cases with no clefting (Group I) (Table I). In 22 cases PIN 
was associated with invasive carcinoma that was found in the same biopsy specimen. 
Prostatic carcinoma was found in 7 cases in same cores, and in 15 cases in other cores of the 
same biopsy.  
The most common Gleason pattern observed in carcinomas was 3 (40 out of 41 cases). 
Twenty-two of tumors were Gleason score 5 and 6, 18 Gleason score 7 and 1 Gleason score 8 
(Table II). Retraction clefting, which affected more than 50% of circumference, was observed 
in 37 of 41 neoplastic cases and in 5 of 41 analyzed benign glands. Sixteen neoplastic and 
none of nonneoplastic cases had 50% or more glands with clefts that affected more that 50% 
of gland circumference (Table I). That difference was statistically significant (p<0.0001). 
There was a statistically significant difference in the frequency and degree of clefting in 
tumorous glands in comparison with PIN (p<0.0001). However, there was no difference 
between normal glands and PIN regarding clefting (p= 0.8064). In 21 tumorous and 5  
nontumorous cases, clefts which affected more than 50% of circumference, were observed but 
affected up to fifteen glands. Four neoplastic and 36 nonneoplastic cases were without clefts 
or with clefts, which affected less than 50% of gland circumference (Table 1). Only basal 
cells were stained by p63. P63 was positive around whole circumference in 12 out of 28 
glands with intraepithelial neoplasia, and discontinuously positive in remaining 16 PIN cases 
suggesting initial disruption of basal cell layer. P63 immunostaining was also positive in all 
nonneoplastic glands, and negative in all carcinoma cases (Table I) (Figure 1).   
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DISCUSSION 
 
As the accurate diagnosis of prostatic carcinoma in the needle core biopsies demands 
sophisticated approach, there are many diagnostic criteria that should be satisfied. Besides 
three major histologic criteria, there are three additional diagnostic features of prostatic 
cancer, including mucinous fibroplasias, glomerulations and perineural invasion that have not 
been identified in benign conditions.5,6,24  Varma et al.24 in their study on 250 needle biopsy 
specimens with prostatic carcinoma found mucinous fibroplasia in only 3 (2%) cases, 
glomerulations in 23 (15.3%) and perineural invasion in 33 (22%) of cases.  There are many 
additional criteria like marginated and/or multiple nucleoli, intraluminal crystalloids, 
intraluminal amorphous eosinophilic material, and others that are used in routine needle core 
biopsy diagnostics.2,7,24 Nowadays, the pathologist is more often confronted with limited 
amounts of carcinoma on fine needle biopsy with an increased risk of confusion with benign 
conditions.5,7,13 In a series of 24 limited carcinoma cases reported by Leroy et al.13, diagnostic 
features for carcinoma were very rarely seen. Perineural invasion was not observed, 
collagenous micronodules were seen in one case only and mucinous fibroplasia not even 
mentioned. 
One of the proposed supportive criterion is a so-called periacinar retraction clefting. 
Halpert et al.8,9 were the first to briefly describe the clefts in autopsy studies in prostatic 
adenocarcinoma in 1960’s. Our previous studies suggest that periacinar clefting is not simply 
technical artifact without significance but instead represent the consequence of processes that 
affected neoplastic acini and surrounding stroma.10-12,22 Standard laboratory procedure 
probably, in a certain way, assists in appearance of clefting but clefts appear more frequently 
and extensively around glands without basal cell layer or glands surrounded with tumorous 
stroma when compared to normal glands. In this way, clefting is visible around neoplastic 
glands and could serve as the reliable and helpful diagnostic criterion.   
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In practice, failure of staining for high molecular weight cytokeratin to demonstrate 
the presence of any basal cells within a collection of glands does not guarantee that those 
glands represent carcinoma. However, the presence of clearly identifiable basal cells in a 
gland or duct does preclude the diagnosis of carcinoma for that structure.25 At least focal high 
molecular weight cytokeratin (clone34betaE12 antibody) positivity was observed in 1.1% of 
3198 prostatic carcinoma cases diagnosed on needle core biopsies.15 All cases were Gleason 
score 6 with a mean number of 36.9 neoplastic glands. HGPIN was present in 64% of these 
cases adjacent to prostatic carcinoma with the mean number of 1.36 glands.15    
Antibodies against high molecular weight cytokeratin (34betaE12) and p63 are 
frequently used basal cell markers to aid in the diagnosis of prostatic carcinoma. Technical 
factors such as tissue fixation and antigen retrieval techniques may also make the detection of 
basal cells difficult.26  Zhou et al. 26 recommended this basal cell cocktail for routine prostatic 
carcinoma diagnostic work-up. 
P63 is a recently introduced nuclear marker that may be useful for separating PIN and 
cancer from benign conditions mimicking cancer. Immunostaining of prostatic tissue, 
including benign glands, PIN and prostatic adenocarcinoma was restricted to basal cell 
nuclei.3 However, experience with p63 is limited to date and caution is urged owing to 
concerns with false-positive and false-negative staining.2 
 A new molecular marker called racemase or AMACR (alpha-methyl-acyl-CoA 
racemase, P504S) was recently applied to separate benign from neoplastic acini.2,4,23 
However, a high proportion of high-grade PIN, as well as some foci of adenosis and some 
entirely benign glands are also positive for this marker.6 
 Because of the cytoplasmic localization of P504S and nuclear localization of p63, 
Tacha and Miller hypothesized that a cocktail of these two antibolies might allow 
simultaneous demonstration of P504S and p63 using a single immunostain.21 The authors 
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concluded that this cocktail could be of great utility in the examination of diagnostically 
challenging prostate specimens.  
Our results are strongly suggesting the connection between the lack of basal cells in 
neoplastic glands and the development of retraction clefting. The results have also shown 
invariably negative staining for p63 in all cancer cases with periacinar retraction artifacts and 
positive staining in PIN cases. We conclude that clefting represent reliable diagnostic criterion 
and that staining for p63 might be needed when retraction clefting affect less then 50% of 
circumference of glands or are not present. Determination of retraction clefting could be 
performed during the routine analysis of specimens under the low magnification and the 
extent of clefting around particular glands under high magnification. This procedure does not 
significantly prolong time needed for routine biopsy evaluation. 
 The value of retraction clefting in the differential diagnosis between adenocarcinoma 
and mimickers of cancer, especially atrophy and postatrophic hyperplasia and adenosis, 
should be further analyzed.  
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Table I. Distribution of periacinar retraction clefting in the glands with intraepithelial 
neoplasia, neoplastic and nonneoplastic glands and p63 immunoreactivity  
 Prostatic intraepithelial 
neoplasia* 
Malignant cases** Benign cases** 
 Number 
of cases 
p63 
immunoreactivity 
Number 
of cases 
p63 
immunoreactivity 
Number 
of cases 
p63 
immunoreactivity 
Group I 23 
(82.1%)
positive in all 
cases 
4 
(9.8%) 
negative in all 
cases 
36 
(87.9%) 
positive in all 
cases 
Group II 5 
(17.9%)
positive in all 
cases 
21 
(51.2%)
negative in all 
cases 
5 
(12.1%) 
positive in all 
cases 
Group III 0 
(0%) 
positive in all 
cases 
16 
(39.0%)
negative in all 
cases 
0 
(0%) 
positive in all 
cases 
Total 28 
(100%) 
positive in all 
cases 
41 
(100%) 
negative in all 
cases 
41 
(100%) 
positive in all 
cases 
 
Legend: 
*Group I - no clefting 
*Group II - clefting affected up to 50% of gland circumference 
*Group III - clefts affected more than 50% of gland circumference 
 
**Group I - glands without clefts or with clefts which affected less than 50% of    
    circumference 
**Group II - up to 50% (less than fifteen) of glands with clefts, which affected more   
    than 50% of circumference 
**Group III - 50% (fifteen) or more glands with clefts, which affected more than 50%   
    of circumference   
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Table II. Distribution of Gleason score among 41 prostatic needle biopsies with prostatic 
adenocarcinoma 
 
Gleason pattern 
with scores 
Number of cases % 
5 (2+3) 5 12.2 
5 (3+2) 6 14.7 
6 (2+4) 1 2.4 
6 (3+3) 10 24.4 
7 (3+4) 11 26.8 
7 (4+3) 7 17.1 
8 (3+5) 1 2.4 
Total 41 100 
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Figure 1. P63 immunostaining in prostatic intraepithelial neoplasia (A) and prostatic 
adenocarcinoma (B). Nonneoplastic glands served as a positive control. (Microphotographs 
were made under high magnification, 400X). 
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